TYK2 and chronic kidney disease: Emerging evidence highlights the role of leukemia inhibitory factor (LIF) in amplifying phosphate-driven calcification via the TYK2/STAT3 pathway, with TYK2 inhibition by deucravacitinib—a clinically approved immunosuppressant—significantly attenuating VC in CKD models (27).